Eisai Recalls Belviq Tablets Due to Missing or Illegible Labels
Eisai Inc. is recalling 121,680 bottles of Belviq (Lorcaserin HCl) 10 mg tablets because some bottles may lack labels or have illegible lot and expiry dates.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 1/5 (Low).
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III and involves a packaging/labeling defect (missing or illegible labels) without reported injuries or illnesses, fitting the 'Low' severity criteria for documentation or packaging-only problems.
Plain-English summary
Eisai Inc. is voluntarily recalling 121,680 bottles of Belviq (Lorcaserin HCl) 10 mg tablets, 60-count bottles, distributed nationwide. The recall is due to a labeling defect where bottles may not have a product label, or may have a label with a missing or illegible lot number and/or expiry date.
The affected product is manufactured by Arena Pharmaceuticals, GmbH, and distributed by Eisai Inc. The specific lots involved are #13297008, #13307008, and #13367008, all with expiration dates in November or December 2015. The NDC number for the product is 62856-52960.
Consumers who have this product should check their bottles for missing or illegible labels. If the label is missing or the lot number and expiry date cannot be read, they should stop using the product and contact their healthcare provider or pharmacist for further instructions.
The recalled product
- Product
- BELVIQ¿ (Lorcaserin HCl) Tablets, 10 mg, 60-count bottle, Rx only, Manufactured by: Arena Pharmaceuticals, GmbH, Zofingen, Switzerland, Distributed by: Elsai Inc., Woodcliff, NJ 07677 NDC 62856-52960.
- Manufacturer
- Eisai Inc
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 121,680
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot #13297008
- Exp. 11/15
- 13307008
- 13367008
- Exp.12/15.
Distribution
Distributed nationwide across the United States.
Related recalls
Same hazard · mis labeling
See all →- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-10-14
- SevereBetter Bakehouse Recalls Donutful Chocolate Dipped Vanilla Cake Donuts for Undeclared Milk
FDA (Food) · 2026-10-14
- HighFreshPoint Recalls Cranberry Chicken Salad Wedges for Undeclared Egg Allergen
FDA (Food) · 2026-10-14
- HighJ K Patisserie & Bakery LLC Recalls Croissants for Undeclared Egg
FDA (Food) · 2026-10-14
- ModerateHalyard Laparoscopy Comprehensive Pack II Recalled for Latex Content
FDA (Devices) · 2026-10-14
Similar recalls
- LowPrinston Recalls Irbesartan and Hydrochlorothiazide Tablets Due to Labeling Error
FDA (Drugs) · 2016-06-29
- SevereBristol-Myers Squibb Recalls Eliquis 5mg Tablets Due to Labeling Error
FDA (Drugs) · 2017-07-19
- LowTeva Recalls Irbesartan and Hydrochlorothiazide Tablets Due to Labeling Errors
FDA (Drugs) · 2015-12-23
- ModerateAidapak Recalls Colchicine Tablets Due to Potential Label Mixup
FDA (Drugs) · 2014-01-22
- LowMobic Tablets Recalled for Incorrect Package Insert Labeling
FDA (Drugs) · 2017-10-18
- ModerateAidapak Recalls Hydrocortisone Tablets Due to Potential Labeling Errors
FDA (Drugs) · 2014-01-29